{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:06:05Z","timestamp":1792994765266,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Hepatitis C virus (HCV) genotype 4 is highly heterogeneous. HCV subtype 4r has been suggested to be less responsive to direct\u2010acting antiviral (DAA) drug treatment than other genotype 4 subtypes. Among 537 DAA\u2010treated patients who experienced a virological failure (VF) in France between 2015 and 2018, 121 (22.5%) were infected with genotype 4 and 27 of them (22.3%) with subtype 4r; subtype 4r was thus over\u2010represented as compared to its prevalence in the French general population. Population sequencing of the nonstructural protein (NS) 3, NS5A, and NS5B genes was performed in all subtype 4r patients at treatment failure and in 6 at baseline, whereas full\u2010length HCV genome sequencing was performed in two baseline and three treatment failure samples by means of an original shotgun metagenomics method based on deep sequencing. At treatment failure, all subtype 4r patients harbored two to three dominant NS5A resistance\u2010associated substitutions (RASs), including at least L28A\/C\/I\/M\/V and L30R. Among 13 patients exposed to sofosbuvir and an NS5A inhibitor (daclatasvir, ledipasvir, or velpatasvir), 5 (38.5%) also harbored NS5B S282C\/T RASs at treatment failure. An additional patient harbored S282C\/T RASs at treatment failure by deep sequencing. Prevalence of S282C\/T RASs at treatment failure was significantly higher in patients infected with genotype 4r than with other genotypes, including other subtypes of genotype 4. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: The lower rates of sustained virological response in patients infected with subtype 4r are related to the frequent preexistence at treatment baseline and subsequent selection by DAA treatment of both NS5A and NS5B S282 RASs. Our study suggests that these patients should be identified and receive a triple DAA combination regimen as first\u2010line treatment.<\/jats:p>","DOI":"10.1002\/hep.30225","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T07:34:21Z","timestamp":1534750461000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":94,"title":["Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r"],"prefix":"10.1097","volume":"69","author":[{"given":"Slim","family":"Fourati","sequence":"first","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[{"name":"INSERM U955,Cr\u00e9teil,France"},{"name":"Department of Hepatology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Soulier","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Ruiz","sequence":"additional","affiliation":[{"name":"INSERM U955,Cr\u00e9teil,France"},{"name":"Department of Hepatology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Poiteau","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Chevaliez","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Pawlotsky","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D,Department of Virology,Henri Mondor Hospital, University of Paris\u2010Est,Cr\u00e9teil,France"},{"name":"INSERM U955,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"hep30225-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep30225-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.27766","article-title":"Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause\u2010specific outcomes","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep30225-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All\u2010oral direct\u2010acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV\u2010coinfected subjects in real\u2010world practice: Madrid coinfection registry findings","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep30225-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.13925","article-title":"Real\u2010world use, effectiveness and safety of anti\u2010viral treatment in chronic hepatitis C genotype 3 infection","volume":"45","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"17","key":"hep30225-bib-0006-20241017","first-page":"32431","article-title":"Real\u2010world effectiveness of 8\u2010week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C","volume":"S0168\u20138278","year":"2017","journal-title":"J Hepatol"},{"key":"hep30225-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real\u2010world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment\u2010naive, genotype 1 hepatitis C\u2010infected patients","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep30225-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP3168","article-title":"Real\u2010world efficacy and safety of ritonavir\u2010boosted paritaprevir, ombitasvir, dasabuvir \u00b1 ribavirin for hepatitis C genotype 1. Final results of the REV1TAL study","volume":"22","year":"2017","journal-title":"Antivir Ther"},{"key":"hep30225-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1136\/gutjnl-2016-312012","article-title":"Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real\u2010world experience","volume":"66","year":"2017","journal-title":"Gut"},{"key":"hep30225-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/tri.12910","article-title":"Real\u2010world experience with daclatasvir plus sofosbuvir \u00b1 ribavirin for post\u2010liver transplant HCV recurrence and severe liver disease","volume":"30","year":"2017","journal-title":"Transpl Int"},{"key":"hep30225-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct\u2010acting antiviral drugs in interferon\u2010free regimens","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30225-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.22127","article-title":"Hepatitis C genotype 4: what we know and what we don't yet know","volume":"47","year":"2008","journal-title":"Hepatology"},{"key":"hep30225-bib-0013-20241017","first-page":"30582","article-title":"Severe liver disease related to chronic hepatitis C virus infection in treatment\u2010naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014","volume":"22","year":"2017","journal-title":"Euro Surveill"},{"key":"hep30225-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/17512433.2016.1233813","article-title":"Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4","volume":"9","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"hep30225-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep30225-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment\u2010naive and treatment\u2010experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL\u2010I): a randomised, open\u2010label trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep30225-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jvh.12896","article-title":"HCV genotype 4, 5 and 6: distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct\u2010acting antiviral regimens","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"hep30225-bib-0018-20241017","first-page":"S50","article-title":"Direct\u2010acting antiviral treatment in sub\u2010saharan Africa: a prospective trial of ledipasvir\/ sofosbuvir for chronic HCV infection in Rwanda (The SHARED Study)","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30225-bib-0019-20241017","first-page":"233","article-title":"Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa","volume":"464\u2010465","year":"2014","journal-title":"Virology"},{"key":"hep30225-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"e42002","DOI":"10.1371\/journal.pone.0042002","article-title":"Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"hep30225-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jvh.12906","article-title":"Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4\u2010infected patients with or without cirrhosis treated with ombitasvir\/paritaprevir\/ritonavir","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"hep30225-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jvh.12795","article-title":"Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"hep30225-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28491","article-title":"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir\u2010containing regimen","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30225-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position\u2010specific gap penalties and weight matrix choice","volume":"22","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"hep30225-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00239-001-0018-9","article-title":"Hepatitis C virus evolutionary patterns studied through analysis of full\u2010genome sequences","volume":"54","year":"2002","journal-title":"J Mol Evol"},{"key":"hep30225-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrg2583","article-title":"Evolutionary analysis of the dynamics of viral infectious disease","volume":"10","year":"2009","journal-title":"Nat Rev Genet"},{"key":"hep30225-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection","volume":"213","year":"2016","journal-title":"J Infect Dis"},{"key":"hep30225-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrg3642","article-title":"Sequencing depth and coverage: key considerations in genomic analyses","volume":"15","year":"2014","journal-title":"Nat Rev Genet"},{"key":"hep30225-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30225-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"e0179064","DOI":"10.1371\/journal.pone.0179064","article-title":"Genetic diversity of hepatitis C virus in Ethiopia","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"hep30225-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/JCM.03548-14","article-title":"Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping","volume":"53","year":"2015","journal-title":"J Clin Microbiol"},{"key":"hep30225-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1038\/s41598-018-22614-0","article-title":"A novel standardized deep sequencing\u2010based assay for hepatitis C virus genotype determination","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"hep30225-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijid.2017.12.016","article-title":"Hepatitis C virus deep sequencing for sub\u2010genotype identification in mixed infections: a real\u2010life experience","volume":"67","year":"2018","journal-title":"Int J Infect Dis"},{"key":"hep30225-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1\u2010infected patients","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep30225-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","year":"2018","journal-title":"Drug Resist Updat"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201902000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:17:34Z","timestamp":1729210654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201902000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30225","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"2018-06-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}